HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania)

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameHER-2/Neu pulsed DC1 vaccine (University of Pennsylvania)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute

Inactive CompaniesNational Cancer Institute

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A